capecitabine has been researched along with Pulmonary Arterial Remodeling in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, Y; Aoshima, K; Asano, M; Funahashi, Y; Kawano, S; Kimura, T; Matsui, J; McCracken, PJ; Nomoto, K; Oda, Y; Okamoto, K; Ozawa, Y; Semba, T; Tizon, X; Tohyama, O; Uehara, T; Uesugi, M; Watanabe, H | 1 |
1 other study(ies) available for capecitabine and Pulmonary Arterial Remodeling
| Article | Year |
|---|---|
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Topics: Animals; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Mice, Inbred BALB C; Tubulin Modulators; Tumor Microenvironment; Vascular Remodeling; Xenograft Model Antitumor Assays | 2014 |